Obesity Drugs Linked to Muscle and Bone Loss, Experts Caution

As of August 2, 2025, experts are raising alarms about the potential long-term health risks associated with the growing use of obesity drugs, particularly GLP-1 injections. According to a recent study, up to 40% of the weight lost on these medications may come from muscle and bone, rather than fat. This could significantly increase the risk of fractures and osteoporosis in the long run.

Doctors have also reported cases of users experiencing gaunt faces, brittle hair, and severe gastrointestinal reactions, with some patients even requiring hospitalization for dehydration. Mental health experts have warned that the drugs' effects on appetite and brain chemistry may be linked to increased anxiety, panic attacks, and restlessness.

Despite these concerns, the use of GLP-1 injections continues to surge in the UK, with an estimated 1.5 million Britons now taking the medication. The country is spending around £190 million per month on these prescriptions, and nearly half of survey respondents reported paying between £50 and £150 per month out of pocket.

Health Secretary Wes Streeting has suggested expanding access to GLP-1 jabs as part of a strategy to help obese people return to work. However, critics warn that this approach risks overlooking the root causes of obesity and providing a costly, risky quick fix.